TWI367759B - A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid - Google Patents

A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid

Info

Publication number
TWI367759B
TWI367759B TW093104283A TW93104283A TWI367759B TW I367759 B TWI367759 B TW I367759B TW 093104283 A TW093104283 A TW 093104283A TW 93104283 A TW93104283 A TW 93104283A TW I367759 B TWI367759 B TW I367759B
Authority
TW
Taiwan
Prior art keywords
rapid
immediate release
gastric acid
novel formulation
sustained suppression
Prior art date
Application number
TW093104283A
Other languages
English (en)
Other versions
TW200509923A (en
Inventor
Bonnie Hepburn
Barry Goldlust
Original Assignee
Santarus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santarus Inc filed Critical Santarus Inc
Publication of TW200509923A publication Critical patent/TW200509923A/zh
Application granted granted Critical
Publication of TWI367759B publication Critical patent/TWI367759B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093104283A 2003-02-20 2004-02-20 A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid TWI367759B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44862703P 2003-02-20 2003-02-20

Publications (2)

Publication Number Publication Date
TW200509923A TW200509923A (en) 2005-03-16
TWI367759B true TWI367759B (en) 2012-07-11

Family

ID=32908619

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093104283A TWI367759B (en) 2003-02-20 2004-02-20 A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid

Country Status (7)

Country Link
US (1) US20040248942A1 (zh)
EP (1) EP1603537A4 (zh)
JP (1) JP2006518751A (zh)
AR (1) AR043258A1 (zh)
CA (1) CA2517005A1 (zh)
TW (1) TWI367759B (zh)
WO (1) WO2004073654A2 (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
CA2603783C (en) * 2005-04-11 2014-11-18 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
CA2602812C (en) * 2005-04-12 2014-11-18 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
US20060276500A1 (en) * 2005-04-26 2006-12-07 Phillips Jeffrey O Compositions and methods for treating nocturnal acid breakthrough and other acid related disorders
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
BRPI0615357A2 (pt) * 2005-08-19 2011-05-17 Aventis Pharma Inc combinação de um agente hipnótico e r (+)-alfa-(2,3-dimetóxi-fenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e aplicação terapêutica do mesmo
US20090104264A1 (en) * 2005-12-28 2009-04-23 Takeda Pharmaceutical Company Limited Controlled release solid preparation
EP1967183A4 (en) * 2005-12-28 2011-02-23 Takeda Pharmaceutical SOLID PREPARATION WITH CONTROLLED RELEASE
PL1976532T3 (pl) * 2006-01-27 2016-05-31 Univ Yale Szybko działający inhibitor wydzielania kwasu żołądkowego
US8512761B2 (en) 2006-01-27 2013-08-20 Yale University Fast acting inhibitor of gastric acid secretion
ES2281292B1 (es) * 2006-03-08 2008-06-16 Quimica Sintetica S.A. Nuevas sales de esomeprazol. procedimiento de preparacion y composiciones farmaceuticas que las comprenden.
WO2008002567A2 (en) * 2006-06-27 2008-01-03 Alza Corporation Methods of treating conditions by sustained release administration of benzimidazole derivatives
EP1880716A1 (en) * 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
JP5474541B2 (ja) * 2006-07-25 2014-04-16 ベクタ・リミテッド 小さいジカルボン酸の誘導体と組み合わせてｐｐｉを用いる胃酸分泌を阻害する組成物および方法
CA2663090A1 (en) * 2006-07-29 2008-02-07 Graceway Pharmaceuticals, Llc Business method to treat and/or prevent a gastric acid disorder with a proton pump inhibitor (ppi) and a cholinergic agonist to induce rapid onset of ppi action with or without food
CA2667682A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US20080166423A1 (en) * 2007-01-06 2008-07-10 Renjit Sundharadas Combination Medication for Treating the Effects of Stomach Acid Reduction Medication on Bone Integrity
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
CN102638978A (zh) * 2009-06-25 2012-08-15 波曾公司 用于治疗需要阿司匹林治疗之患者的方法
CA2774094A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
WO2013142383A1 (en) 2012-03-21 2013-09-26 Cosmederm Bioscience, Inc. Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
AU2012379005B2 (en) 2012-05-02 2017-12-21 Newmarket Pharmaceuticals Llc Pharmaceutical compositions for direct systemic introduction
US20160250253A1 (en) * 2013-09-24 2016-09-01 Cosmederm Bioscience, Inc. Strontium-containing complexes for treating gastroesophageal reflux and barrett's esophagus
JP6443891B2 (ja) * 2014-01-31 2018-12-26 塩野義製薬株式会社 徐放性製剤
US11590165B2 (en) * 2014-12-17 2023-02-28 Bausch Health Companies Inc. Formulations of calcium and phosphate for oral inflammation
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102276547B1 (ko) * 2020-09-04 2021-07-13 주식회사유한양행 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법
CN111870583B (zh) * 2020-09-28 2020-12-18 上海翰森生物医药科技有限公司 一种注射用艾司奥美拉唑钠冻干制剂及其制备方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045564A (en) * 1974-02-18 1977-08-30 Ab Hassle Benzimidazole derivatives useful as gastric acid secretion inhibitors
IN148930B (zh) * 1977-09-19 1981-07-25 Hoffmann La Roche
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
SE8604566D0 (sv) * 1986-10-27 1986-10-27 Haessle Ab Novel compunds
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
NZ224252A (en) * 1987-04-21 1991-09-25 Erba Carlo Spa An anthracycline glycoside and its preparation
GB8809421D0 (en) * 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
EP0425505B1 (en) * 1988-06-30 1993-03-17 The Upjohn Company Transdermal antisecretory agents for gastrointestinal disease
SE8804628D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New compounds
EG19302A (en) * 1988-12-22 1994-11-30 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
ATE114114T1 (de) * 1989-02-10 1994-12-15 Takeda Chemical Industries Ltd Verwendung von benzimidazol-derivaten als antibakterielle mittel.
SE8903563D0 (sv) * 1989-10-26 1989-10-26 Haessle Ab A novel dissolution system
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
HUT62882A (en) * 1990-06-20 1993-06-28 Astra Ab Process for producing dialkoxy pyridylmethyl sulfinyl benzimidazole derivatives and pharmaceutical compositions comprising same
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
US5215874A (en) * 1991-01-21 1993-06-01 Fuji Photo Film Co., Ltd. Silver halide photographic material having magnetic recording member
US5244670A (en) * 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
TW224049B (zh) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
TW276996B (zh) * 1992-04-24 1996-06-01 Astra Ab
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
US5447918A (en) * 1992-07-27 1995-09-05 Mccullough; Ricky W. Gastrointestinal anti-irritant composition comprising sucralfate and methods of use
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
US5935600A (en) * 1993-09-10 1999-08-10 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing comestible unit and product therefrom
AU7833194A (en) * 1993-09-20 1995-04-10 Procter & Gamble Company, The Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
ES2179079T3 (es) * 1993-10-12 2003-01-16 Mitsubishi Pharma Corp Comprimidos que contienen granulos entericos.
TW280770B (zh) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
CA2180535C (en) * 1994-01-05 2004-03-23 Lindberg, Per Lennart A method for treatment of psoriasis, by omeprazole or related compounds
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
JPH11513679A (ja) * 1995-10-17 1999-11-24 アストラ・フアーマシユウテイカルズ・リミテツド 薬剤活性キナゾリン化合物
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6169102B1 (en) * 1996-06-25 2001-01-02 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use as anti-Helicobacter pylori agent
US5766622A (en) * 1996-08-14 1998-06-16 The Procter & Gamble Company Inhibiting undesirable taste in oral compositions
AU3691297A (en) * 1996-08-15 1998-03-06 Losan Pharma Gmbh Easy to swallow oral medicament composition
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
US5939091A (en) * 1997-05-20 1999-08-17 Warner Lambert Company Method for making fast-melt tablets
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
AU751066B2 (en) * 1997-12-08 2002-08-08 Nycomed Gmbh Novel administration form comprising an acid-labile active compound
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
CA2298823C (en) * 1998-04-20 2011-06-07 Eisai Co., Ltd. Stabilized composition comprising a benzimidazole type compound
US6047829A (en) * 1998-09-18 2000-04-11 Westvaco Corporation Unit dose packaging system (UDPS) having a child resistant locking feature
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7111317B1 (en) * 2000-03-24 2006-09-19 Eastman Kodak Company Method for providing image goods and/or services to a customer
CA2374760A1 (en) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
US6555139B2 (en) * 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6572900B1 (en) * 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
EP1404300B1 (en) * 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs

Also Published As

Publication number Publication date
EP1603537A4 (en) 2009-11-04
WO2004073654A3 (en) 2005-01-13
AR043258A1 (es) 2005-07-20
CA2517005A1 (en) 2004-09-02
EP1603537A2 (en) 2005-12-14
TW200509923A (en) 2005-03-16
WO2004073654A2 (en) 2004-09-02
US20040248942A1 (en) 2004-12-09
JP2006518751A (ja) 2006-08-17

Similar Documents

Publication Publication Date Title
TWI367759B (en) A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
EP1796641A4 (en) NEW FORMULATION, OMEPRAZOL ANTAZIDA COMPLEX WITH IMMEDIATE RELEASE FOR THE RAPID AND CONTINUOUS SUPPRESSION OF MAGIC ACID
IL160117A0 (en) Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption
IL166431A0 (en) Microcapsules with modified release of active principles with low solubility for oral delivery
TWI347202B (en) Controlled release preparation
PL373914A1 (en) Immediate release dosage forms containing solid drug dispersions
IL183982A0 (en) Controlled release formulation for oral administration for treating diabetes containing metformin and methods for the preparation thereof
IL181301A0 (en) Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof
HK1189346A1 (zh) 具有活性成分位點和時間-可控胃腸釋放的片劑
IL173300A0 (en) Compositions for encapsulation and controlled release
IL174560A0 (en) Controlled release formulations of opioid and nonopioid analgesics
AU2003215334A1 (en) Inhalable formulations for sustained release
ZA200501084B (en) Dispersible tablets for oral administration
TWI319318B (en) Modified release pharmaceutical formulation
EP1553925A4 (en) ORAL DOSAGE FORM WITH MODIFIED RELEASE
HK1156311A1 (zh) 製備吡啶酸類抗菌藥物
IL229510A0 (en) A dosage form containing pantoprazole as an active ingredient
IL164153A0 (en) Lansoprazole polymorphs and processes for preparation thereof
EP1648416A4 (en) PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD
AU2003260803A8 (en) Sustained release pharmaceutical composition
EP1750767A4 (en) PHARMACEUTICAL FORMULATIONS USEFUL IN INHIBITING ACID SECRETION AND METHODS OF MAKING AND USING SAME
EP1765340A4 (en) COMPOSITION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION OF NIACIN
AU2003284942A8 (en) Oral extended release tablets and methods of making and using the same
PL1848439T3 (pl) Doustna formulacja o natychmiastowym uwalnianiu słabo rozpuszczalnej w wodzie substancji aktywnej
GB2404856B8 (en) Stable pharmaceutical composition of rabeprazole

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees